Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
UBS
AstraZeneca
McKinsey
Citi
Harvard Business School
Chinese Patent Office
Federal Trade Commission
Express Scripts

Generated: October 21, 2017

DrugPatentWatch Database Preview

Sunovion Company Profile

« Back to Dashboard

What is the competitive landscape for SUNOVION, and what generic alternatives to SUNOVION drugs are available?

SUNOVION has nine approved drugs.

There are forty-four US patents protecting SUNOVION drugs on SUNOVION drugs in the past three years.

There are five hundred and sixty-eight patent family members on SUNOVION drugs in forty-eight countries and forty-three supplementary protection certificates in fourteen countries.

Summary for Applicant: Sunovion

International Patents:568
US Patents:44
Tradenames:9
Ingredients:9
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-002Nov 8, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-002Nov 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-003Nov 8, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-003Nov 8, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Sunovion Pharms Inc
ZONEGRAN
zonisamide
CAPSULE;ORAL020789-003Aug 22, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sunovion

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
XOPENEX HFA
levalbuterol tartrate
AEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-001Dec 15, 2004► Subscribe► Subscribe
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion
XOPENEX HFA
levalbuterol tartrate
AEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-001Dec 15, 2004► Subscribe► Subscribe
Sunovion Pharms Inc
LUNESTA
eszopiclone
TABLET;ORAL021476-002Dec 15, 2004► Subscribe► Subscribe
Sunovion
XOPENEX HFA
levalbuterol tartrate
AEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
Sunovion
XOPENEX HFA
levalbuterol tartrate
AEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
Sunovion
XOPENEX HFA
levalbuterol tartrate
AEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SUNOVION drugs

Drugname Dosage Strength Tradename Submissiondate
lurasidone hydrochloride
Tablets20 mg, 40 mg, 60 mg, 80 mg, and 120 mg
LATUDA
10/28/2014
arformoterol tartrate
Inhalation SolutionEq. 0.015 mg base/2 mL
BROVANA
10/1/2009
eszopiclone
Tablets1 mg, 2 mg and 3 mg
LUNESTA
12/15/2008

Non-Orange Book Patents for Sunovion

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,605,260Process for producing imide compound► Subscribe
9,566,239Pharmaceutical formulations for dry powder inhalers► Subscribe
7,732,641Formoterol tartrate process and polymorph► Subscribe
8,623,922Bronchodilating Beta-agonist compositions and methods► Subscribe
8,258,139Method of treatment for mental disorders► Subscribe
9,040,559BETA2-adrenoceptor agonists► Subscribe
7,223,748Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
5,780,632 Imide derivatives and their production and use► Subscribe
8,101,160Formulations for use in inhaler devices► Subscribe
9,351,928Method of making particles for use in a pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sunovion Drugs

Country Document Number Estimated Expiration
United Kingdom0029265► Subscribe
TaiwanI359020► Subscribe
European Patent Office1449528► Subscribe
Canada2429665► Subscribe
Germany60132239► Subscribe
South Korea101166955► Subscribe
Japan5698423► Subscribe
China1422154► Subscribe
Portugal1267866► Subscribe
Canada2538265► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sunovion Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
651Luxembourg► Subscribe91651, EXPIRES: 20241130
2010 00006Denmark► Subscribe
166Luxembourg► SubscribePRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS
0Finland► Subscribe
2014000092Germany► SubscribePRODUCT NAME: LURASIDON, INSBESONDERE EINE PHARMAZEUTISCH VERTRAEGLICHE SALZFORM UND IM SPEZIELLEN DAS HYDROCHLORIDSALZ DAVON; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321
14/051Ireland► SubscribePRODUCT NAME: LURASIDONE, PARTICULARLY A PHARMACEUTICALLY ACCEPTABLE SALT FORM AND ESPECIALLY THE HYDROCHLORIDE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321
/2014Austria► SubscribePRODUCT NAME: LURASIDON, GEGEBENENFALLS IN FORM SEINER FREIEN BASE ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON.; REGISTRATION NO/DATE: EU/1/14/913 20140327
C/GB10/009United Kingdom► SubscribePRODUCT NAME: INDACATEROL OR A SALT THEREOF; REGISTERED: UK EU/1/09/593/001 20091130; UK EU/1/09/593/002 20091130; UK EU/1/09/593/003 20091130; UK EU/1/09/593/004 20091130; UK EU/1/09/593/005 20091130; UK EU/1/09/593/006 20091130; UK EU/1/09/593/007 20091130; UK EU/1/09/593/008 20091130; UK EU/1/09/593/009 20091130; UK EU/1/09/593/010 20091130
2014034Lithuania► SubscribePRODUCT NAME: LURASIDONUM; REGISTRATION NO/DATE: EU/1/14/913 20140321
2014 00020Denmark► SubscribePRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, ISAER BROMIDSALTET, I KOMBINATION MED INDACATEROL ELLER ET SALT DERAF, ISAER MALEATSALTET; REG. NO/DATE: EU/1/13/862 20130919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Dow
Argus Health
Express Scripts
Mallinckrodt
Harvard Business School
Novartis
Queensland Health
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot